Genedata at SBI2 will Showcase How Genedata Screener Industrializes HCS

Used by the world’s leading research organizations, Screener for HCS is the most effective, streamlined decision-making platform for image-based screening

Cambridge, MA, September 14, 2015

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, announced it will be among the presenters at the 2nd Annual Society of Biomolecular Imaging and Informatics (SBI2) Meeting.  At SBI2’s Data Analysis Colloquium, Genedata will discuss Genedata Screener for HCS, the platform that more than half of the Top 25 pharma and leading research institutes rely upon for data analysis of image-based screening. Genedata will also demonstrate new solution enhancements for HCS in the recently announced Genedata Screener® version 13.0, such as improved image displays and new functionality for multi-parametric feature selection and quality control in an automated, screening-specific workflow. SBI2, a global scientific event for HCS/HCA, will be held at the Joseph B. Martin Conference Center, Harvard Medical School where Genedata will exhibit at Booth #G2 (Sept. 15-17).

HCS is all about Images – Screener for HCS Enables Instant Access

As the range of assays, instruments, and user groups increases, so does the complexity of high content screening (HCS). For individual researchers and more importantly enterprises, HCS can be a perfect storm of data analysis challenges, requiring scientists to spend costly time on repetitive tasks that do not necessarily drive deep understanding of the relationship between data and biology.

There is a mandate to reduce the time spent on routine tasks so that scientists are free to focus on the science and results of their experiments -- not data handling. To address these issues, organizations and scientists must scale-up and streamline their HCS analysis workflow, aiming for an industrialized approach to data analysis. Supporting the complete data analysis workflow, Genedata Screener industrializes HCS. It offers integrations with most HCS systems and makes HCS an integral part of the enterprise screening workflow, including the required experiment annotations and results upload to the data warehouse.

Leveraging the enhancements in the new Genedata Screener version 13.0, Screener for HCS now includes:

  • optimized usability such as context-specific image displays, at a single click;
  • completely automated analysis from single cells to end results;
  • interactive definition and analysis of cell populations; and
  • advanced statistics and visualizations for feature exploration and reduction.

Furthermore, Genedata Screener customers can now analyze High Throughput Flow Cytometry experiments alongside HCS. New functionality for data processing from Drug Metabolism and Pharmacokinetics (DMPK) screens, as well as enhancements for Thermal Shift, and Surface Plasmon Resonance (SPR) screening experiments are also built into the new Genedata Screener 13.0, which will be released for general availability on October 6, 2015.

“We are very excited about this latest release of Genedata Screener as it is a major milestone in our plan to streamline and automate the complex data analysis process for HCS,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata is highly committed to addressing the rapidly emerging customer requirements for HCS data analysis. Our domain knowledge gained from working with leading high content screening practitioners from around the world coupled with our collaborative business model, allows us to build Screener, making it the de facto standard in screening activities for both small research organizations and large enterprises.”


About Genedata

Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.

Follow Genedata on LinkedIn



The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.